TMPRSS2 and pachyonychia congenita: Studies have additionally investigated whether TMPRSS2-ERG gene fusions can be utilised to assess PC aggressiveness in patients undergoing AS, thereby having use as a prognostic biomarker when assessed in prostatic tissues samples [190].